MA-ONE-DOOR
20.4.2021 14:03:04 CEST | Business Wire | Press release
One Door, Inc., the leading provider of cloud-based visual merchandising software, today announced a new multi-year agreement with the Woolworths Group. Woolworths will implement One Door’s Merchandising Cloud platform across its supermarkets to simplify and streamline work for its in-store merchandising teams.
“We are thrilled to partner with Woolworths to have a positive impact on the lives of their customers and team,” said Tom Erskine, CEO of One Door.
“Woolworths is a proven retail innovator and we both believe we are only just beginning to jointly understand how these technologies can ultimately improve the work experience for store teams and improve the overall customer experience.”
“We’re pleased to partner with One Door to roll out Merchandising Cloud for the benefit of our teams and customers,” said Doug Frank, Woolworths General Manager Group Data & Analytics.
“One Door allows us to simplify a critical and time intensive task - making life easier for in-store merchandisers and helping ensure our products are presented to customers the right way.
“As we continue to tailor and localise our range in different stores, it’s important we draw on the best technology to make it simpler for our stores to execute for our customers.
Merchandising Cloud is built for store teams first, transforming the way retailers plan, execute, and analyze their in-store merchandising. Merchandising Cloud is the only platform that converts existing, legacy planograms and floorplans into a mobile-first, interactive experience that guides store teams through tasks step-by-step, and shows them not just what to do, but how to do it.
Once work is complete, Merchandising Cloud uses AI-based Computer Vision and analytics to streamline real-time audits and provide insight into merchandising compliance and performance in every store. The result is more efficiency in stores, and a higher quality store experience.
About One Door
One Door, Inc. is the leading provider of cloud-based visual merchandising software. With One Door, space planners, visual merchandisers and store operations teams work across silos to plan, execute and analyze store merchandising plans in a unified, cloud-based platform. The result is higher sales, more store team efficiency, and better customer experiences. Learn more at https://onedoor.com/execution-compliance/
About Woolworths Group
Woolworths Group is a fresh food, drinks and everyday needs retailer united by a shared purpose of creating better experiences together for a better tomorrow. With more than 3,000 stores across its Woolworths Supermarkets, Countdown Supermarkets (New Zealand), BIG W, Dan Murphy’s and BWS brands, Woolworths Group is Australia and New Zealand’s largest retailer. A top 20 company on the Australian Securities Exchange (ASX), Woolworths Group employs more than 215,000 team members and serves more than 29 million customers every week. In FY20, Woolworths Group reported sales of $63.6bn (AUD), including $3.5bn in online sales.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005114/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom